Therapeutic intensive seizure analysis (TISA) in presurgical evaluation of Losigamone.
OBJECTIVE
The new method TISA was used to evaluate Losigamone efficacy.


METHODS
Sixteen patients with pharmacoresistant partial seizures undergoing presurgical evaluation were randomized in this double-blind, placebo-controlled, parallel-group Losigamone monotherapy study under continuous video-EEG monitoring. Duration (in s, of each seizure and each ictal sign), intensity (grade zero to three), N/24h (number of seizures and ictal signs per 24 h), D/24h (seconds per 24 h covered by seizures and ictal signs) and seizure free intervals were recorded.


RESULTS
A total of 246 seizures were intensively analyzed. The duration and intensity of all seizures improved more in the active treatment group than in the placebo group. There was a statistically significant superiority in the duration of the seizure free interval in the Losigamone group. Ictal signs such as oro-alimentary automatisms and fumbling were improved during Losigamone treatment.


CONCLUSIONS
Losigamone has a preferred inhibitory effect on propagated epileptic activity. TISA is a sensitive method for evaluation of the selective effects of AEDs.
Stefan
H
H
Department of Neurology, Epilepsy Center, University of Erlangen-Nuernberg, 91054 Erlangen, Germany. hermann.stefan@neuro.med.uni-erlangen.de
Wang
Y
Y
Kerling
F
F
Hopp
P
P
Zhou
D
D
Dienel
A
A
Feichtinger
M
M
Kirchner
A
A
Pauli
E
E
D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology*; D004311:Double-Blind Method; D004569:Electroencephalography; D005260:Female; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012640:Seizures / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000927:Anticonvulsants; D005663:Furans; C065427:losigame